ANTIBODIES AND MARKERS OF DISEASE ACTIVITY IN PATIENTS WITH AUTOIMMUNE DISEASES

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。有新的数据表明，患有自身免疫性疾病的患者会产生针对多种细胞、细胞表面分子、调节蛋白及其配体的抗体。为了确定患病率，从而确定临床意义，重要的是收集患有各种自身免疫性疾病的患者的队列。这些血清和血浆样本将作为UAB的风湿病学家和免疫学家的宝贵资源，为进一步研究提供初步数据，以评估自身免疫性疾病的发病机制，从而提供更好的治疗方法。本项目的目标是建立一个来自类风湿性关节炎（RA）、系统性红斑狼疮（SLE）、血管炎或骨关节炎（OA）、血清阴性脊柱炎（SNSA）和硬皮病（PSS）患者的血清和血浆库。在UAB的流变学诊所招募的约450名RA、SLE、血管炎和OA患者将采集总计40 ml orf血液用于血清和血浆。此外，还将审查他们的医疗记录，以获得基本的人口统计学数据：年龄、种族、性别、疾病数据（发病年份、器官受累、疾病活动和当前药物）。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. There is emerging data that patients with autoimmune diseases develop antibodies to a variety of cells, cell surface molecules, regulatory proteins, and their ligands. In order to determine the prevalence, and thus clinical significance, it is important to collect a cohort of patients with a variety of autoimmune diseases. These samples of serum and plasma will serve as a valuable resource to rheumatologists and immunologists at UAB to provide preliminary data for additional studies to evaluate the pathogenesis of autoimmune diseases, and thus better therapies. The goal of this project is to develop a repository of serum and plasma from patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), vasculitis or osteoarthntis (OA), seronegative spondylitis (SNSA) and scleroderma (PSS). Approximately 450 patients with RA, SLE, vasculitis, and OA, recruited in the Rheumatology clinics at UAB, will have a total of 40 ml orf blood drawn for serum and plasma. Also, their medical records will be reviewed to obtain basic demographic data: age, race, gender, disease data (year of onset, organ involvement, disease activity, and current medications).